Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 5/20 | 0.42 |
| ▸ | ATP4B | P51164 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475624 | 0.92 | ATP4A (0.48) | ATP4AATP4BMAPTALDH1A1MEN1 | |
| SCHEMBL3695840 | 0.91 | ATP4A (0.52) | ATP4AATP4BALDH1A1MEN1KMT2A | |
| SCHEMBL6474148 | 0.86 | ATP4A (0.47) | ATP4AATP4BMAPTALDH1A1MEN1 | |
| SCHEMBL6481789 | 0.84 | ATP4A (0.36) | ATP4AATP4BMAPTALDH1A1MEN1 | |
| SCHEMBL6475880 | 0.83 | ATP4A (0.49) | ATP4AATP4BMAPTALDH1A1MEN1 | |
| SCHEMBL6476845 | 0.82 | ATP4A (0.50) | ATP4AATP4BMAPTALDH1A1MEN1 | |
| SCHEMBL12809663 | 0.81 | ATP4A (0.38) | ATP4AATP4BMAPTALDH1A1MEN1 | |
| SCHEMBL8381037 | 0.81 | VCP (0.40) | ATP4AATP4BMAPTALDH1A1MEN1 | |
| SCHEMBL6475030 | 0.80 | ATP4A (0.45) | ATP4AATP4BMAPTALDH1A1MEN1 | |
| SCHEMBL8812759 | 0.80 | ALDH1A1 (0.35) | ATP4AATP4BMAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524837-B2 | Benzotriazapinone salts and methods for using same | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-28 | — | — | US | disclosed |
| EP-1971363-A1 | COMBINATION TREATMENTS WITH GASTRIN AGONISTS FOR DIABETES AND RELATED DISEASES | Waratah Pharmaceuticals, Inc. (CA) | 2008-09-24 | — | — | EP | disclosed |
| EP-1951286-A1 | COMBINED USE OF DPP IV INHIBITORS AND GASTRIN COMPOUNDS | Waratah Pharmaceuticals, Inc. (CA) | 2008-08-06 | — | — | EP | disclosed |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| WO-2007062531-A1 | COMBINATION TREATMENTS WITH GASTRIN AGONISTS FOR DIABETES AND RELATED DISEASES | WARATAH PHARMACEUTICALS, INC. (CA) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007041833-A1 | COMBINED USE OF DPP IV INHIBITORS AND GASTRIN COMPOUNDS | WARATAH PHARMACEUTICALS, INC. (CA) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082892-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| US-7105558-B2 | Gastrin and cholecystokinin receptor lignads (iv) | THE JAMES BLACK FOUNDATION LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| WO-2006051312-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
| US-7034048-B2 | Gastrin and cholecystokinin receptor ligands (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2006-04-25 | — | — | US | disclosed |
| US-20030199565-A1 | Gastrin and cholecystokinin receptor ligands(II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-23 | — | — | US | disclosed |
| US-20030195237-A1 | Gastrin and cholecystokinin receptor lignads (iv) | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| US-20030195240-A1 | Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| US-20030191116-A1 | Gastrin and cholecystokinin receptor ligands (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-09 | — | — | US | disclosed |
| WO-2003041714-A1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-05-22 | — | — | WO | disclosed |
| WO-2001090078-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS GASTRIN AND CHOLECYSTOKIN IN RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001085704-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (IV) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085724-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085723-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-1993012817-A1 | THERAPEUTIC COMBINATIONS USEFUL IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE | WARNER-LAMBERT COMPANY (US) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195237-A1 | Gastrin and cholecystokinin receptor lignads (iv) | CCKAR, CCKBR, GRPR | ATP4A 3174/4885ATP4B 2600/4885MAPT 4796/4885 |
| US-20030191116-A1 | Gastrin and cholecystokinin receptor ligands (III) | CCKAR, CCKBR, GRPR | ATP4A 1849/4885ATP4B 2902/4885MAPT 4833/4885 |
| US-20070082892-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | ATP4A 1951/4885ATP4B 1893/4885MAPT 2666/4885 |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | ATP4A 1951/4885ATP4B 1893/4885MAPT 2666/4885 |
| US-20030199565-A1 | Gastrin and cholecystokinin receptor ligands(II) | GRPR, CCKBR, GIPR | ATP4A 1033/4885ATP4B 1138/4885MAPT 4604/4885 |
| US-20030195240-A1 | Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands | GIPR, CCKAR, CCKBR | ATP4A 557/4885ATP4B 644/4885MAPT 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.